Insulin-lowering drugs in polycystic ovary syndrome (Q34212186)

31 July 2017

1 reference

title

Insulin-lowering drugs in polycystic ovary syndrome (English)

1 reference

polycystic ovary syndrome

31 July 2017

1 reference

1 reference

1 reference

Iuorno MJ

1

1 reference

PubMed ID

11293000

31 July 2017

Nestler JE

series ordinal

2

1 reference

31 July 2017

1 March 2001

1 reference

Obstetrics and Gynecology Clinics of North America

31 July 2017

1 reference

31 July 2017

28

1 reference

31 July 2017

153-164

1 reference

31 July 2017

1

1 reference

Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin.

31 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Identification of placental protein 14 as an immunosuppressive factor in human reproduction

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Insulin-like growth factor-I enhances luteinizing hormone binding to rat ovarian theca-interstitial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Insulin resistance in nonobese patients with polycystic ovarian disease

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Cellular mechanisms of insulin resistance in polycystic ovarian syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Metformin in management of pregnant insulin-independent diabetics

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Metformin improved insulin resistance in type I, insulin-dependent, diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Paracrine actions of insulin-like growth factors and IGF binding protein-1 in non-pregnant human endometrium and at the decidual-trophoblast interface

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Mediators of postreceptor action of insulin

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Insulin-signaling mechanisms. Lessons from the old testament of glycogen metabolism and the new testament of molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

High ovulatory rates with use of troglitazone in clomiphene-resistant women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Suppression of serum insulin level by diazoxide does not alter serum testosterone or sex hormone-binding globulin levels in healthy, nonobese women

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Suppression by Human Placental Protein 14 of Natural Killer Cell Activity

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Recurrent early miscarriage and polycystic ovaries

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Low levels of low molecular weight insulin-like growth factor-binding protein in patients with polycystic ovarian disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Troglitazone enhances differentiation, basal glucose uptake, and Glut1 protein levels in 3T3-L1 adipocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Habitual abortion is accompanied by low serum levels of placental protein 14 in the luteal phase of the fertile cycle

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Obesity, lipids, cardiovascular risk, and androgen excess

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

Lipid and apolipoprotein abnormalities in hirsute women. I. The association with insulin resistance

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8545%2805%2970191-1

7 January 2021

10.1016/S0889-8545(05)70191-1

Identifiers

DOI

1 reference

31 July 2017

1 reference

PubMed ID

11293000